Cancer models play a crucial role in the drug development process. Initially, cell lines are used for high-throughput screening of potential drug compounds. Promising candidates are then tested in PDX or GEMMs to evaluate their efficacy and safety in a more complex biological context. Organoid models can provide insights into how individual patients might respond to a treatment, facilitating the development of personalized therapies. Finally, computational models can predict treatment outcomes and optimize drug dosing.
